#layer4F5D495769ABAB7DB1F5721C1EF40D84 .search_btn {border: 0px solid #fff;border-radius: 0px;color: #fff;}#layer4F5D495769ABAB7DB1F5721C1EF40D84 .search_btn a {color: #fff!important;}#layer4F5D495769ABAB7DB1F5721C1EF40D84 .search_btn:hover {background-color: #000!important;border-color: #fff;color: #fff;}#layer4F5D495769ABAB7DB1F5721C1EF40D84 .search_btn:hover a {color: #fff!important;}

MicroPort: Translating Biomedical Innovation into Global Therapeutics

MicroPort is a globally recognized medical technology company headquartered in Shanghai, with a mission to bring life-saving therapies to patients around the world. Since its founding in 1998, MicroPort has grown into a diversified healthcare firm spanning cardiovascular devices, neurointervention, orthopedics, diabetes care, and oncology.

  • 01

    Technology Strengths

    The company is especially known for its stents, pacemakers, and orthopedic implants, developed through an R&D network that spans China, the United States, and Europe. Its in-house innovation pipeline includes next-generation drug-eluting stents, AI-guided surgical systems, and smart insulin pumps.

     

    MicroPort emphasizes translational research — turning scientific discoveries into practical medical applications. It works closely with hospitals and clinicians to conduct multicenter clinical trials, gather real-world evidence, and accelerate product approval through global regulatory channels.

  • 02

    International Collaboration and Partnership

    To enhance its scientific foundation, MicroPort partners with institutions like Harvard Medical School and the University of Oxford, collaborating on areas such as targeted oncology drugs, bioresorbable materials, and regenerative medicine. These partnerships aim to blend academic rigor with clinical practicality.

     

    In an age of rising global health demands and demographic shifts, MicroPort is committed to co-developing therapies that are not only innovative but also accessible — meeting unmet needs in emerging and mature healthcare markets alike.